Your browser doesn't support javascript.
loading
Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer.
Luo, Zhangyi; Xu, Jieni; Sun, Jingjing; Huang, Haozhe; Zhang, Ziqian; Ma, Weina; Wan, Zhuoya; Liu, Yangwuyue; Pardeshi, Apurva; Li, Song.
Afiliación
  • Luo Z; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Xu J; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Sun J; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Huang H; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Zhang Z; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Ma W; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Wan Z; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Liu Y; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Pardeshi A; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States.
  • Li S; Center for pharmacogenetics, Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15261, United States; University of Pittsburgh Cancer Institute, University of Pittsburgh, PA 15261, United States. Electronic address: Sol4@pitt.edu.
Acta Biomater ; 105: 239-252, 2020 03 15.
Article en En | MEDLINE | ID: mdl-31958597
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Profármacos / Desoxiglucosa / Glutamina / Micelas / Neoplasias Límite: Animals / Female / Humans Idioma: En Revista: Acta Biomater Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Profármacos / Desoxiglucosa / Glutamina / Micelas / Neoplasias Límite: Animals / Female / Humans Idioma: En Revista: Acta Biomater Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido